Trimerbody Pharma is a company developing bispecific tumor targeted antibodies based on its highly innovative protein engineering platform Trimerbody®.

Trimerbodies provide several advantages over conventional monoclonal antibodies, such as simultaneous multiple targeting (up to six different targets per molecule), reduced size, higher avidity for targets, and a variety of effector possibilities (immune system activation, receptor blocking, delivery of toxins or cytokines).   

Trimerbody is a novel class of proprietary multivalent and multispecific therapeutic proteins based on specific antigen-binding domains and the unique structural and functional properties of naturally occurring collagen trimerization domains. LeadArtis’s proprietary platform allows rapid generation and production of novel biological therapeutics with potential in a wide range of human diseases.
 
The technology was originally developed following the discovery that fully functional multivalent and multispecific antibodies could be generated by employing certain engineered collagen trimerization domains and target antigen binding domains consisting of conventional single-chain antibody fragments (scFv), single-domain antibodies or antibody mimetics.  As a result, the recombinant Trimerbodies display enhanced antigen-binding capacity and are very stable. 
 
Trimerbodies, with their unique structural and functional properties, form the basis of a new generation of therapeutic molecules, which due to their small size and unique structure are ideal for the generation of novel biological drugs with multiple competitive advantages over other therapeutic molecules.

LeadArtis development portfolio focusses on therapeutic areas such as immuno-oncology and inflammatory-autoimmune diseases. LeadArtis offers also licensing opportunities, offering its Trimerbody® technology to biopharmaceutical companies.

Trimerbody Pharma

Org chart

Teams

Offices